

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Levamisole / Oxfendazole Formulation  
Other means of identification : Scanda (A007130)

**Manufacturer or supplier's details**

Company name of supplier : MSD  
Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product  
Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Acute toxicity (Oral) : Category 5  
Reproductive toxicity : Category 1B  
Specific target organ toxicity : Category 2 (Liver, Testis)  
- repeated exposure  
Specific target organ toxicity : Category 2 (Blood, Testis)  
- repeated exposure (Oral)

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.  
H360FD May damage fertility. May damage the unborn child.  
H373 May cause damage to organs (Liver, Testis) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.

## Levamisole / Oxfendazole Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 10808160-00006      Date of last issue: 06.07.2024  
Date of first issue: 05.07.2022

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P312 Call a POISON CENTER or doctor/ physician if you feel unwell.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Levamisole hydrochloride	16595-80-5	$\geq 5$ -< 10
oxfendazole	53716-50-0	$\geq 1$ -< 5
Polyethylene glycol stearate	9004-99-3	$\geq 1$ -< 5
Citric acid	77-92-9	$\geq 1$ -< 5

**SECTION 4. FIRST AID MEASURES**

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.  
May damage fertility. May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g., by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapors.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
oxfendazole	53716-50-0	TWA	40 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Polyethylene glycol stearate	9004-99-3	VLE-PPT	10 mg/m <sup>3</sup>	NOM-010-

## Levamisole / Oxfendazole Formulation

Version 3.0      Revision Date: 14.04.2025      SDS Number: 10808160-00006      Date of last issue: 06.07.2024  
Date of first issue: 05.07.2022

				STPS-2014
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : Aqueous solution

Color : No data available

Odor : No data available

Odor Threshold : No data available

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

**SECTION 10. STABILITY AND REACTIVITY**

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

## SECTION 11. TOXICOLOGICAL INFORMATION

## Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

## Acute toxicity

May be harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 2,250 mg/kg  
Method: Calculation method

**Components:****Levamisole hydrochloride:**

Acute oral toxicity	:	LD50 (Rat): 180 mg/kg
		LD50 (Mouse): 223 mg/kg
		LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available

**oxfendazole:**

Acute oral toxicity	:	LD50 (Rat): > 6,000 mg/kg
		LD50 (Dog): 1,600 mg/kg
		LD50 (sheep): 250 mg/kg

**Polyethylene glycol stearate:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
---------------------	---	---------------------------

**Citric acid:**

Acute oral toxicity	:	LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg
		Method: OECD Test Guideline 402

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Levamisole hydrochloride:**

Remarks : No data available

**oxfendazole:**

Species : Rabbit  
Result : No skin irritation

**Polyethylene glycol stearate:**

Species : Rabbit  
Method : Draize Test  
Result : No skin irritation

**Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Levamisole hydrochloride:**

Remarks : No data available

**oxfendazole:**

Species : Rabbit  
Result : No eye irritation

**Polyethylene glycol stearate:**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

**Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405



**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Levamisole hydrochloride:**

Remarks	: No data available
---------	---------------------

**Polyethylene glycol stearate:**

Test Type	: Open epicutaneous test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Levamisole hydrochloride:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative

**oxfendazole:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Oral Result: positive

**Polyethylene glycol stearate:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	--

**Citric acid:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: in vitro micronucleus test Result: positive

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Genotoxicity in vivo	Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Species: Rat
	Application Route: Ingestion
	Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Levamisole hydrochloride:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 80 mg/kg body weight
Remarks	: No significant adverse effects were reported

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 40 mg/kg body weight
Remarks	: No significant adverse effects were reported

**oxfendazole:**

Species	: Rat
Application Route	: Oral
Exposure time	: 1 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Symptoms	: No adverse effects.
Target Organs	: Liver

**Reproductive toxicity**

May damage fertility. May damage the unborn child.

**Components:****Levamisole hydrochloride:**

Effects on fertility	Test Type: Three-generation reproduction toxicity study
	Species: Rat
	Application Route: Oral
	Result: No significant adverse effects were reported
Effects on fetal development	Test Type: Embryo-fetal development
	Species: Rat
	Application Route: Oral

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**oxfendazole:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male  
Application Route: Oral  
Fertility: NOAEL: 17 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.9 mg/kg body weight  
Target Organs: Liver  
Result: No effects on fertility.

Test Type: Fertility  
Species: Mouse  
Application Route: Oral  
Duration of Single Treatment: 1 Months  
Fertility: NOAEL: 750 mg/kg body weight  
Target Organs: Testes  
Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: positive, Fetal effects.

Test Type: Embryo-fetal development  
Species: Rat  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: positive, Embryo-fetal toxicity.

Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 108 mg/kg body weight  
Result: positive, Embryo-fetal toxicity., Fetal abnormalities.

Test Type: Embryo-fetal development  
Species: Rabbit

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Application Route: Oral  
Developmental Toxicity: NOAEL: 0.625 mg/kg body weight

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on fetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT-single exposure**

Not classified based on available information.

**Components:****Citric acid:**

Assessment : May cause respiratory irritation.

**STOT-repeated exposure**

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

**Components:****Levamisole hydrochloride:**

Target Organs : Blood, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**oxfendazole:**

Routes of exposure : Oral  
Target Organs : Liver, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Levamisole hydrochloride:**

Species : Rat  
NOAEL : 2.5 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Testis

Species : Dog

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood

Species	: Dog
LOAEL	: 40 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

**oxfendazole:**

Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis

Species	: Rat
NOAEL	: 3.8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis

Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver

Species	: Mouse
NOAEL	: 37.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver

Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland

Species	: Dog
NOAEL	: 13.5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

**Citric acid:**

Species	: Rat
NOAEL	: 4,000 mg/kg
LOAEL	: 8,000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Levamisole hydrochloride:**

Ingestion	: Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension
-----------	--

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Levamisole hydrochloride:**

Toxicity to fish	: LC50 ( <i>Oryzias latipes</i> (Japanese medaka)): 37.3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 ( <i>Daphnia magna</i> (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

**oxfendazole:**

Toxicity to fish	: LC50 ( <i>Lepomis macrochirus</i> (Bluegill sunfish)): > 2.7 mg/l Exposure time: 96 h  LC50 ( <i>Oncorhynchus mykiss</i> (rainbow trout)): > 2.5 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 ( <i>Daphnia magna</i> (Water flea)): 0.059 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC ( <i>Pseudokirchneriella subcapitata</i> (green algae)): > 4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

**Polyethylene glycol stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l  
Exposure time: 96 h  
Method: DIN 38412

Toxicity to microorganisms : EC10 (Bacteria): > 10,000 mg/l  
Exposure time: 16 h

**Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

**Persistence and degradability****Components:****oxfendazole:**

Stability in water : Hydrolysis: < 5 % (4 d)

**Polyethylene glycol stearate:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: > 70 %  
Exposure time: 10 d  
Method: OECD Test Guideline 302B

**Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**Bioaccumulative potential****Components:****oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

**Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

## Levamisole / Oxfendazole Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

**Mobility in soil****Components:****oxfendazole:**

Distribution among environmental compartments : log Koc: 3.2

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxfendazole)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(oxfendazole)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxfendazole)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F



**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****NOM-002-SCT**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxfendazole)
Class	: 9
Packing group	: III
Labels	: 9

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, : Not applicable  
essential chemical products and machinery for  
producing capsules, tablets and pills.

**The ingredients of this product are reported in the following inventories:**

AICS	: not determined
DSL	: not determined
IECSC	: not determined

**SECTION 16. OTHER INFORMATION**

Revision Date	: 14.04.2025
Date format	: dd.mm.yyyy

**Full text of other abbreviations**

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
NOM-010-STPS-2014	: Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits
ACGIH / TWA	: 8-hour, time-weighted average
NOM-010-STPS-2014 / VLE-	: Time weighted average limit value
PPT	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -

**Levamisole / Oxfendazole Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	10808160-00006	Date of first issue: 05.07.2022

---

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8